ReviewTherapeutics and clinical risk management2026
Maternal, Fetal, and Neonatal Outcomes of Additional Dihydroartemisinin-Piperaquine to Trimethoprim-Sulfamethoxazole in Intermittent Preventive Treatment for Malaria in HIV-Positive Pregnancies: A Systematic Review and Meta-Analysis.
Review in Therapeutics and clinical risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This systematic review evaluates the addition of Dihydroartemisinin-Piperaquine (DHA-PPQ) to Trimethoprim-Sulfamethoxazole (TMP-SMX) for Intermittent Preventive Treatment (IPT) in HIV-positive pregnancies, focusing on its effects on malaria infection, maternal adverse events, fetal adverse events, and birth outcomes. Patients and Methods: Following PRISMA guidelines, we searched PubMed, Cochrane, Google Scholar, and Scopus until December 16, 2024. Out of 390 studies, three were included, assessed for bias using ROB 2.0, and analyzed with random-effects meta-analysis in RevMan 5.4.1. Results: We analyzed three studies involving 1353 participants who received 800/160 mg of TMP-SMX, with or without 40/320 mg of DHA-PPQ administered three times. The addition of DHA-PPQ showed a non-significant trend toward lower malaria infection outcomes, including maternal parasitaemia (OR: 0.83; 95% CI [0.52, 1.33], p = 0.44) and rates of placental malaria (OR: 0.66; 95% CI [0.40, 1.08], p = 0.10). DHA-PPQ significantly lowered maternal adverse events (OR: 0.78; 95% CI [0.67, 0.91], p = 0.003), which included low hemoglobin (OR: 0.83; 95% CI [0.69, 1.00], p = 0.05), gastrointestinal events (OR: 0.66; 95% CI [0.46, 0.95], p = 0.03), neurological events (OR: 0.61; 95% CI [0.22, 1.69], p = 0.35), and skin reactions (OR: 0.40; 95% CI [0.08, 2.11], p = 0.28). No significant differences were observed in fetal adverse events (OR: 1.05; 95% CI [0.68, 1.65], p = 0.69), which comprised spontaneous abortion (OR: 1.81; 95% CI [0.60, 5.51], p = 0.30), stillbirth (OR: 1.02; 95% CI [0.55, 1.89], p = 0.95), and congenital anomalies (OR: 0.89; 95% CI [0.32, 2.47], p = 0.83). Finally, no significant effect was observed on birth outcomes (OR: 1.13; 95% CI [0.88, 1.45], p = 0.81), including low birth weight (OR: 1.15; 95% CI [0.85, 1.56], p = 0.36) and premature birth (OR: 1.08; 95% CI [0.70, 1.68], p = 0.73). Conclusion: Additional DHA-PPQ shows promising efficacy in reducing malaria infection, a statistically significant reduction in maternal adverse events, with no significant differences in fetal and birth outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.